Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug

European Journal of Medicinal Chemistry

Volumn 50, Issue , 2012, Pages 179-195

  Hayashi, Shigeo ^a   Ueno, Naomi ^a   Murase, Akio ^a   Nakagawa, Yoko ^a   Takada, Junji ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Carrageenan induced oedema; COX 2 COX 1 selectivity; Inflammation; NSAID; Orally active COX 2 inhibitor

Indexed keywords

2 [6 FLUORO 2 [4 METHYL 2 PRIDINYL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [2 [(4 ETHYLPYRIDIN 2 YL)CARBONYL] 5 (TRIFLUOROMETHOXY) 1H INDOL 3 YL]ACETIC ACID; [2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 5 (TRIFLUOROMETHOXY) 1H INDOL 3 YL]ACETIC ACID; [5 ETHYL 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [5 FLUORO 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [5 METHOXY 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [5 TERT BUTYL 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [6 CHLORO 2 (5,6,7,8 TETRAHYDROISOQUINOLIN 3 YLCARBONYL) 1H INDOL 3 YL]ACETIC ACID; [6 CHLORO 2 [(5 CHLORO 4 ETHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [6 CHLORO 5 FLUORO 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [6 ETHYL-2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; [6 METHOXY 2 [(4 METHYLPYRIDIN 2 YL)CARBONYL] 1H INDOL 3 YL]ACETIC ACID; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SYNTHESIS; FOOT EDEMA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; EDEMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MALE; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84858446155     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.01.053     Document Type: Article

References (68)

1. Review: D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 56 2004 387 437
2. Review: C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875
3. H.U. Zeilhofer Prostanoids in nociception and pain Biochem. Pharmacol. 73 2007 165 174
4. Review: H. Vanegas, and H.-G. Schaible Prostaglandins and cyclooxygenases in the spinal cord Prog. Neurobiol. 64 2001 327 363
5. Review: F. Kojima, M. Kapoor, S. Kawai, and L.J. Crofford New insights into eicosanoid biosynthetic pathways: implication for arthritis Expert Rev. Clin. Immunol. 2 2006 277 291
6. Y. Sugimoto, S. Narumiya, and A. Ichikawa Distribution and function of prostanoid receptors: studies from knockout mice Prog. Lipid Res. 39 2000 289 314
7. T. Hla, and K. Neilson Human cyclooxygenase-2 cDNA Proc. Natl. Acad. Sci. U.S.A 89 1992 7384 7388
8. G.P. O'Neill, and A.W. Ford-Hutchinson Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues FEBS Lett. 330 1993 156 160
9. A.A. Romanovsky, M.C. Almeida, D.M. Aronoff, A.I. Ivanov, J.P. Konsman, A.A. Steiner, and V.F. Turek Fever and hypothermia in systemic inflammation: recent discoveries and revisions Front. Biosci. 10 2005 2193 2216
10. P. Patrignani, M.R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, F. Cipollone, A. Ganci, C. Créminon, J. Maclouf, and C. Patrono Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J. Pharmacol. Exp. Ther. 271 1994 1705 1712
11. R.Y. Kang, J. Freire-Moar, E. Sigal, and C.-Q. Chu Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis Br. J. Rheumatol. 35 1996 711 718
12. F. Beiche, S. Scheuerer, K. Brune, G. Geisslinger, and M. Goppelt-Struebe Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation FEBS Lett. 390 1996 165 169
13. Review: S.A. Steer, and J.A. Corbett The role and regulation of COX-2 during viral infection Viral Immunol. 16 2003 447 460
14. J. Duque, M.D. Díaz-Muñoz, M. Fresno, and M.A. Iñiguez Up-regulation of cyclooxygenase-2 by interleukin-1β in colon carcinoma cells Cell. Signal. 18 2006 1262 1269
15. D.J. Kelley, J.R. Mestre, K. Subbaramaiah, P.G. Sacks, S.P. Schantz, T. Tanabe, H. Inoue, J.T. Ramonetti, and A.J. Dannenberg Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells Carcinogenesis 18 1997 795 799
16. S. Kiritoshi, T. Nishikawa, K. Sonoda, D. Kukidome, T. Senokuchi, T. Matsuo, T. Matsumura, H. Tokunaga, M. Brownlee, and E. Araki Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy Diabetes 52 2003 2570 2577
17. S. Hayashi, Y. Sumi, N. Ueno, A. Murase, and J. Takada Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship Biochem. Pharmacol. 82 2011 755 768
18. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, and J.R. Vane Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Proc. Natl. Acad. Sci. U.S.A. 96 1999 7563 7568
19. Z.A. Radi, and N.K. Khan Effects of cyclooxygenase inhibition on the gastrointestinal tract Exp. Toxicol. Pathol. 58 2006 163 173
20. L. Laine GI risk and risk factors of NSAIDs J. Cardiovasc. Pharmacol. 47 Suppl. 1 2006 S60 S66
21. Review: J.A. Mitchell, and T.D. Warner Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy Br. J. Pharmacol. 128 1999 1121 1132
22. M.L. Kowalski, and J. Makowska Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity. Safety of cyclo-oxygenase-2 inhibitors Treat. Respir. Med. 5 2006 399 406
23. W.B. White, G. Faich, J.S. Borer, and R.W. Makuch Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib Am. J. Cardiol. 92 2003 411 418
24. B. Hinz, B. Renner, and K. Brune Drug insight: cyclo-oxygenase-2 inhibitors - a critical appraisal Nat. Clin. Pract. Rhum. 3 2007 552 560
25. A.A. Steiner, A.I. Ivanov, J. Serrats, H. Hosokawa, A.N. Phayre, J.R. Robbins, J.L. Roberts, S. Kobayashi, K. Matsumura, P.E. Sawchenko, and A.A. Romanovsky Cellular and molecular bases of the initiation of fever PLoS Biol. 4 2006 1517 1524
26. Review: J.R. Vane, and R.M. Botting The mechanism of action of aspirin Thromb. Res. 110 2003 255 258
27. A.A. Khan, M. Iadarola, H.-Y.T. Yang, and R.A. Dionne Expression of COX-1 and COX-2 in a clinical model of acute inflammation J. Pain 8 2007 349 354
28. For example: K.K. Wu Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts Prostaglandins Other Lipid Mediat. 83 2007 175 181
29. O. Dormond, A. Foletti, C. Paroz, and C. Rüegg NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis Nat. Med. 7 2001 1041 1047
30. Q.-T. Zhao, S.-Q. Yue, Z. Cui, Q. Wang, X. Cui, H.-H. Zhai, L.-H. Zhang, and K.-F. Dou Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis Life Sci. 80 2007 484 492
31. C. Iwata, M.R. Kano, A. Komuro, M. Oka, K. Kiyono, E. Johansson, Y. Morishita, M. Yashiro, K. Hirakawa, M. Kaminishi, and K. Miyazono Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis Cancer Res. 67 2007 10181 10189
32. Min/+ mouse model of intestinal tumorigenesis Carcinogenesis 27 2006 382 391
33. J.-H. Chen, C.-W. Wu, H.-L. Kao, H.-M. Chang, A.F.-Y. Li, T.-Y. Liu, and C.-W. Chi Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor Cancer Lett. 239 2006 263 270
34. B.S. Reddy, and C.V. Rao Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors J. Environ. Pathol. Toxicol. Oncol. 21 2002 155 164
35. K. Krysan, K.L. Reckamp, S. Sharma, and S.M. Dubinett The potential and rationale for COX-2 inhibitors in lung cancer Anti-Cancer Agents Med. Chem. 6 2006 209 220
36. R. Chenevard, D. Hürlimann, M. Béchir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R.E. Gay, M. Neidhart, B. Michel, T.F. Lüscher, G. Noll, and F. Ruschitzka Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation J. Am. Heart Assoc. 107 2003 405 409
37. K. Höcherl, F. Dreher, A. Kurtz, and M. Bucher Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure Hypertension J. Am. Heart Assoc. 40 2002 947 953
38. P.S. Staats Pain management and beyond: evolving concepts and treatments involving cyclooxygenase inhibition J. Pain Symptom Manage. 24 1S 2002 S4 S9
39. W.L. Xie, J.G. Chipman, D.L. Robertson, R.L. Erikson, and D.L. Simmons Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing Proc. Natl. Acad. Sci. U.S.A. 88 1991 2692 2696
40. B.A. Patel, C.B. Ziegler, N.A. Cortese, J.E. Plevyak, T.C. Zebovitz, M. Terpko, and R.F. Heck Palladium-catalyzed vinylic substitution reactions with carboxylic acid derivatives J. Org. Chem. 42 1977 3903 3907
41. J.P. Knowles, and A. Whiting The Heck-Mizoroki cross-coupling reaction: a mechanistic perspective Org. Biomol. Chem. 5 2007 31 44
42. A. Agrawal, and P.G. Tratnyek Reduction of nitro aromatic compounds by zero-valent iron metal Environ. Sci. Technol. 30 1996 153 160
43. T.-L. Ho, and D.-G. Jou Synthesis of cryptolepine and cryptoteckiene from a common intermediate Helv. Chim. Acta 85 2002 3823 3827
44. A.C. Cain, and E.R. Holler Extended scope of in situ iodotrimethylsilane mediated selective reduction of benzylic alcohols Chem. Commun. 13 2001 1168 1169
45. R.W. Carling, P.D. Leeson, K.W. Moore, J.D. Smith, C.R. Moyes, I.M. Mawer, S. Thomas, T. Chan, R. Baker, A.C. Foster, S. Grimwood, J.A. Kemp, G.R. Marshall, M.D. Tricklebank, and K.L. Saywell 3-Nitro-3,4-dihydro-2(1H)- quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors J. Med. Chem. 36 1993 3397 3408
46. R.T. Shuman, P.L. Ornstein, J.W. Paschal, and P.D. Gesellchen An improved synthesis of homoproline and derivatives J. Org. Chem. 55 1990 738 741
47. F.H. Case, and T.J. Kasper The preparation of some substituted 2,6-bis-(2-pyridyl)-pyridines J. Am. Chem. Soc. 78 1956 5842 5844
48. F. Fontana, F. Minisci, M.C.N. Barbosa, and E. Vismara Homolytic acylation of pyridines and pyrazines with α-keto acids: the problem of monoacylation J. Org. Chem. 56 1991 2866 2869
49. G.W. Gribble, and M.G. Saulnier Regioselective ortho lithiation of halopyridines Tetrahedron Lett. 21 1980 4137 4140
50. D. Riendeau, M.D. Percival, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, J.-P. Falgueyret, A.W. Ford-Hutchinson, R. Gordon, G. Greig, M. Gresser, J. Guay, S. Kargman, S. Léger, J.A. Mancini, G. O'Neill, M. Ouellet, I.W. Rodger, M. Thérien, Z. Wang, J.K. Webb, E. Wong, L. Xu, R.N. Young, R. Zamboni, P. Prasit, and C.-C. Chan Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor Br. J. Pharmacol. 121 1997 105 117
51. P.F. Moore, D.L. Larson, I.G. Otterness, A. Weissman, S.B. Kadin, F.J. Sweeney, J.D. Eskra, A. Nagahisa, M. Sakakibara, and T.J. Carty Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties Inflamm. Res. 45 1996 54 61
52. C. Brideau, S. Kargman, S. Liu, A.L. Dallob, E.W. Ehrich, I.W. Rodger, and C.-C. Chan A human whole blood assays for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors Inflamm. Res. 45 1996 68 74
53. 2 production Inflamm. Res. 45 1996 246 253
54. K. Glaser, M.-L. Sung, K. O'Neill, M. Belfast, D. Hartman, R. Carlson, A. Kreft, D. Kubrak, C.-L. Hsiao, and B. Weichman Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1 Eur. J. Pharmacol. 281 1995 107 111
55. W.L. Smith, R.M. Garavito, and D.L. DeWitt Prostaglandin endoperoxide H synthase (cyclooxygenase)-1 and -2 J. Biol. Chem. 271 1996 33157 33160
56. M.G. Malkowski, S.L. Ginell, W.L. Smith, and R.M. Garavito The productive conformation of arachidonic acid bound to prostaglandin synthase Science 289 2000 1933 1937
57. C.A. Winter, E.A. Risley, and G.V. Nuss Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs Proc. Soc. Exp. Biol. Med 111 1962 544 547
58. J.G. Lombardino, I.G. Otterness, and E.H. Wiseman Acidic anti-inflammatory agents-correlations of some physical, pharmacological and clinical data Arzneim. Forsch. 25 1975 1629 1635
59. J. Gracia Leme, L. Hamamura, M.P. Leite, and M. Rocha e Silva Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating Br. J. Pharmacol. 48 1973 88 96
60. F. Nantel, D. Denis, R. Gordon, A. Northey, M. Cirino, K.M. Metters, and C.C. Chan Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation Br. J. Pharmacol. 128 1999 853 859
61. S. Cuzzocrea, L. Sautebin, G. De Sarro, G. Costantino, L. Rombolá, E. Mazzon, A. Ialenti, A. De Sarro, G. Ciliberto, M. Di Rosa, A.P. Caputi, and C. Thiemermann Role of IL-6 in the pleurisy and lung injury caused by carrageenan J. Immunol. 163 1999 5094 5104
62. M. Romano, R. Faggioni, M. Sironi, S. Sacco, B. Echtenacher, E. Di Santo, M. Salmona, and P. Ghezzi Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor Mediat. Inflamm. 6 1997 32 38
63. S.S.V. Padi, N.K. Jain, S. Singh, and S.K. Kulkarni Pharmacological profile of paracoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor Eur. J. Pharmacol. 491 2004 69 76
64. I. Posadas, M. Bucci, F. Roviezzo, A. Rossi, L. Parente, L. Sautebin, and G. Cirino Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression Br. J. Pharmacol. 142 2004 331 338
65. 2-induced mouse paw edema J. Pharmacol. Exp. Ther. 318 2006 611 618
66. S. Hayashi, E. Nakata, A. Morita, K. Mizuno, K. Yamamura, A. Kato, and K. Ohashi Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H- benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships Bioorg. Med. Chem. 18 2010 7675 7699
67. S. Hayashi, A. Hirao, A. Imai, H. Nakamura, Y. Murata, K. Ohashi, and E. Nakata Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl] -1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug J. Med. Chem. 52 2009 610 625
68. S. Hayashi, A. Hirao, H. Nakamura, K. Yamamura, K. Mizuno, and H. Yamashita Discovery of 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3- piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable, and potential-risk reduced novel non-peptide nociceptin/orphanin FQ receptor agonist as antianxiety drug Chem. Biol. Drug Des. 74 2009 369 381